Kryptor

The Kryptor second-generation chromogranin A assay. Clin Chem Lab Med. 2016 Nov 1;54(11):e335-e337.2709265339. van der Knaap RHP, Kwekkeboom DJ, Ramakers CRB, de Rijke YB. Evaluation of a new immunoassay for chromogranin A measurement on the Kryptor system. Pract Lab Med. 2015 Mar 10;1:5-11.2893279340. Wolf M, Riedlinger I, Lehmann R, Häring HU, Schleicher E, Peter A. Comparison of the automated KRYPTOR chromogranin A assay with the DAKO ELISA. Clin Lab. 2014;60(12):2103-2106.2565174841. Spadaro A, Ajello A, Morace C, et al. Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits. World J Gastroenterol. 2005 Apr 7;11(13):1987-1990.1580099142. Giovanella L, Marelli M, Ceriani L, Giardina G, Garancini S, Colombo L. Evaluation of chromogranin A expression in serum and tissues of breast cancer patients. Int J Biol Markers. 2001 Oct-Dec;16(4):268-272.1182072343. Marotta V, Zatelli MC, Sciammarella C, et al. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: More flaws than fame. Endocr Relat Cancer. 2018 Jan;25(1):R11-R29.2906650344. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A—biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol. 2010 Sep;17(9):2427-2443.2021725745. Molina R, Alvarez E, Aniel-Quiroga A, et al. Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies. Tumour Biol. 2011 Feb;32(1):13-22.2073052046. Kidd M, Bodei L, Modlin IM. Chromogranin A: any relevance in neuroendocrine tumors? Curr Opin Endocrinol Diabetes Obes. 2016 Feb;23(1):28-37.2662772447. Mosli HH, Dennis A, Kocha W, Asher LJ, Van Uum SH. Effect of short-term proton pump inhibitor treatment

1. BRAHMS CgA II KRYPTOR® IFU-839R-USA [package insert]. Middletown, VA: Fisher Scientific Company LLC; 2015.2. Borges R, Daz-Vera J, Domnguez N, Arnau MR, Machado JD. Chromogranins as regulators of exocytosis. J Neurochem. 2010 Jul;114(2):335-343.204560133. D'amico MA, Ghinassi B, Izzicupo P, Manzoli L, Di Baldassarre A. Biological function and clinical relevance of chromogranin A and derived peptides. Endocr Connect. 2014 Apr 29;3(2):R45-54.246711224. Bartolomucci A, Possenti R, Mahata SK, Fischer-Colbrie R, Loh YP, Salton SR. The extended granin family: structure, function, and biomedical implications. Endocr Rev. 2011 Dec;32:755-797.218626815. Ardill JE, O'Dorisio TM. Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators. Endocrinol Metab Clin North Am. 2010 Dec;39(4):777-790.210955446. Strosberg JR, Halfdanarson TR, Bellizzi AM, et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas. 2017 Jul;46(6):707-714.286093567. Citterio D, Pusceddu S, Facciorusso A, et al. Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver. Eur J Surg Oncol. 2017 Feb;43(2):380-387.279563208. Gut P, Czarnywojtek A, Fischbach J, et al. Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls. Arch Med Sci. 2016 Feb 1;12(1):1-9.269251139. Yao JC, Pavel M, Lombard-Bohas C, et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: Overall survival and circulating biomarkers from the randomized, Phase III RADIANT-3 Study. J Clin Oncol. 2016 Nov 10;34(32):3906-3913.2762139410. Yang X, Yang Y, Li Z, et al. Diagnostic value of circulating chromogranin a for neuroendocrine tumors:

B·R·A·H·M·S Procalcitonin (PCT) AssayWhen seconds count, accurate results can make the difference between life and deathThe Siemens Healthineers B·R·A·H·M·S PCT assay can help improve sepsis patient outcomes and can also help to reduce unnecessary treatments and costs for healthcare institutions.Help achieve early sepsis risk assessment to improve patient outcomes, including reduced morbidity and mortality with the ability to make confident decisions in minutes.Gain confidence when guiding antibiotic therapy with an assay that has optimal precision across the measurable range.Deliver reliable results from proven, trusted technologies that demonstrate high agreement with the B·R·A·H·M·S PCT sensitive KRYPTOR assay.Trusted Results Across SystemsAntibiotic Decision-MakingInterpretation of ResultsRapid results in the ER with PCTData support the following interpretative risk assessment criteria on first day of ICU admission:7,8PCT>2.0 ng/mL: Associated with a high risk for progression to severe sepsis and/or septic shock.PCTNote: PCT levels Did this information help you?1de Jong E, van Oers J, Beishuizen A, Vos P, Vermeijden W, Haas L, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: A randomised, controlled, open-label trial. Lancet Infect Dis. 2016 Jul 1;16(7):819-27.2Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: The ProHOSP randomized controlled trial. Jama. 2009 Sep 9;302(10):1059-66.3Esposito S, Tagliabue C, Picciolli I, Semino M, Sabatini C, Consolo S, et al. Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia. Respir Med. 2011 Dec;105(12):1939-45. 4Kyriazopoulou E, Liaskou-Antoniou L, Adamis G, Panagaki A, Melachroinopoulos N, Drakou E, Marousis K, et al. Procalcitonin to reduce long-term infection-associated adverse events in sepsis. a randomized trial. Amer J Resp Crit. 2021 Jan 15;203(2):202-10. 5Long W, Deng X, Zhang YU, Lu G, Xie J, Tang J. Procalcitonin guidance for reduction of antibiotic